lobbying_activities: 3152817
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3152817 | 55749dda-cc46-4dad-90a3-b60e0126a53f | Q1 | COREWELL HEALTH | 298455 | COREWELL HEALTH | 2024 | first_quarter | PHA | 340B PBM Reform/Oversight Regulation of controlled substances via telehealth prescribing practices Transparency and high costs associated with prescription drugs | Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,SENATE | 180000 | 0 | 0 | 2024-04-18T17:17:19-04:00 |